NVO News and Press, Novo Nordisk A/S From 07/17/24

2024-07-17 14:09:20 ET More on AbbVie, Bristol-Myers, etc. Is Bristol-Myers Squibb's Rich Dividend Yield Worth The Patent Cliff Correction Risk? Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript Don't Let The Market Fool You: Bristol-Myers Is Not A Value T...

2024-07-17 13:28:09 ET Summary Rotation trade sees shift to cyclical and defensive sectors. Housing starts rose 3.0% M/M in June. JNJ posted better-than-expected results. Listen below or on the go on Apple Podcasts and Spotify Money continues to l...

2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...

2024-07-17 07:36:37 ET More on Eli Lilly, Novo Nordisk, etc. What Eli Lilly Is Getting With The Acquisition Of Morphic Holding Wall Street Lunch: Merger Monday In All Its Glory Eli Lilly Targets IBD, Takes Calculated Gamble With $3.2bn Morphic Deal Novo Nordi...

2024-07-16 08:10:00 ET Summary Stock market investing is not a zero-sum game, offering long-term potential for growth and income when it comes to highly undervalued stocks. Bristol Myers Squibb stock is undervalued, with strong revenue growth, profitability, and a promising drug p...

2024-07-15 15:19:54 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo’s Ozempic linked to improved brain health: s...

2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...

2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...

2024-07-13 15:34:06 ET More on Eli Lilly, ResMed, etc. What Eli Lilly Is Getting With The Acquisition Of Morphic Holding Wall Street Lunch: Merger Monday In All Its Glory Eli Lilly Targets IBD, Takes Calculated Gamble With $3.2bn Morphic Deal Lilly expecting ...

2024-07-13 14:03:47 ET More on Amgen, Biogen, etc. Biogen's Diverse Drug Portfolio Faces Competitive Challenges In 2024 Merck: Positive Developments, But Watch The Q2 Earnings Biogen Stock: Cheapish, But With Few Growth Prospects This weight loss stock is the...